Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Name:	eyeg_CommitmentsAndContingenciesLineItems
Namespace Prefix:	eyeg_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Number of years after the date of the first commercial sale of a product containing the licensed technology, in CCYY-MM-DD format.

No definition available.

Name:	eyeg_LicenseExpirationPeriod
Namespace Prefix:	eyeg_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

This element represents the amount of cash inflow for upfront payment.

No definition available.

Name:	eyeg_ProceedsFromUpfrontPayment
Namespace Prefix:	eyeg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Area of land held.

No definition available.

Name:	us-gaap_AreaOfLand
Namespace Prefix:	us-gaap_
Data Type:	num:areaItemType
Balance Type:	na
Period Type:	instant

Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Name:	us-gaap_LicenseCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

A description of the overall arrangement.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

Name:	us-gaap_RevenueRecognitionMilestoneMethodDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=eyeg_NewValeantAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyeg_LicensorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyeg_ValeantPharmaceuticalsInternationalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: